| Literature DB >> 27384561 |
Zhili Liang1, Lin Li2,3,4, Haiping Qi5, Xia Zhang6, Zhenbo Xu7,8, Bing Li9,10.
Abstract
Pyrraline, a causative factor for the recent epidemics of diabetes and cardiovascular disease, is also employed as an indicator to evaluate heat damage and formation of advanced glycation end-products (AGEs) in foods. Peptide-enriched drinks (PEDs) are broadly consumed worldwide due to rapid rate of absorption and perceived health effects. It can be hypothesized that PED is an important source of pyrraline, especially peptide bound pyrraline (Pep-Pyr). In this study we determined free-form pyrraline (Free-Pyr) and Pep-Pyr in drinks enriched with whey protein hydrolysate (WPH), soy protein hydrolysate (SPH) and collagen protein hydrolysate (CPH). A detection method was developed using ultrahigh-performance liquid chromatography with UV-visible detector coupled with tandem mass spectrometry after solid-phase extraction (SPE). The SPE led to excellent recovery rates ranging between 93.2% and 98.5% and a high reproducibility with relative standard deviations (RSD) of <5%. The limits of detection and quantification obtained were 30.4 and 70.3 ng/mL, respectively. Pep-Pyr was identified as the most abundant form (above 96 percent) of total pyrraline, whereas Free-Pyr was present in a small proportion (less than four percent) of total pyrraline. The results indicate that PED is an important extrinsic source of pyrraline, especially Pep-Pyr. As compared with CPH- and SPH-enriched drinks, WPH-enriched drinks contained high content of Pep-Pyr. The Pep-Pyr content is associated with the distribution of peptide lengths and the amino acid compositions of protein in PEDs.Entities:
Keywords: Maillard reaction; advanced glycation end products; protein hydrolysates; pyrraline; solid-phase extraction
Mesh:
Substances:
Year: 2016 PMID: 27384561 PMCID: PMC4964429 DOI: 10.3390/ijms17071053
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Derivatization of 3-deoxyglucosone (3-DG) by o-phenylenediamine (OPD).
Figure 2Free form and peptide bound pyrraline formation derived from Lys and peptides, individually.
Figure 3Effect of addition amount of o-phenylenediamine (OPD) on measured 3-DG quinoxaline (3-DGqx) content in Peptide-enriched drinks (PEDs).
Repeatability and recovery rates of different concentrations of pyrraline and 3-DG.
| RSD a | RSD a | RSD a | RSD a | ||||||
|---|---|---|---|---|---|---|---|---|---|
| pyrraline | μg/mL b | 63.5 | 34.6 | 10.0 | 0.5 | ||||
| Recovery | 98.5% | 2.5% | 95.4% | 2.3% | 94.1% | 4.8% | 93.2% | 3.4% | |
| 3-DG | μg/mL c | 48.6 | 26.3 | 10.0 | 0.5 | ||||
| Recovery | 99.2% | 5.6% | 96.3% | 6.5% | 95.6% | 5.3% | 94.7% | 6.3% |
a Relative standard deviations (RSD); b Concentration of pyrraline in pyrraline-free matrix (PFM); c Concentration of 3-DG in 3-DG free matrix.
Figure 4Relationship between volume of washing solvent and recovery of pyrraline (a); and relationship between volume of elution solvent and recovery of pyrraline (b). (a) Volume of elution solvent was 4 mL, the recovery obtained using the least volume of the washing solvent (1 mL) was taken as 100, and the data were expressed as relative peak area; (b) Volume of washing solvent was 2 mL, the recovery obtained using the volume of the elution solvent (7 mL) was taken as 100, and the data were expressed as relative peak area
Figure 5UPLC-UV chromatogram recorded at 297 nm of pyrraline in PEDs: (a) before SPE procedure; and (b) after SPE procedure.
Figure 6Product ion scan of pyrraline in a PED sample recorded by UPLC-UV-MS/MS (parent ion, m/z 255.1330).
Concentrations of free-form and peptide bound pyrraline in 27 commercial PEDs.
| Sample | Peptide Source | Free-Form Pyrraline (mg/100 g of Protein) | Peptide Bound Pyrraline (mg/100 g Protein) | Total Pyrraline (mg/100 g of Protein) |
|---|---|---|---|---|
| Group 1 | ||||
| PED1 | WPH | nd | 45.23 ± 1.95 | 45.23 ± 1.95 |
| PED2 | WPH | 5.60 ± 1.15 | 76.05 ± 0.60 | 81.70 ± 0.38 |
| PED3 | WPH | tr | 52.65 ± 2.30 | 52.65 ± 2.30 |
| PED4 | WPH | nd | 59.15 ± 1.58 | 59.15 ± 1.58 |
| PED5 | WPH | tr | 56.10 ± 0.30 | 56.10 ± 0.30 |
| PED6 | WPH | 7.75 ± 0.75 | 27.03 ± 0.58 | 34.78 ± 1.33 |
| PED7 | WPH | nd | 56.18 ± 0.35 | 56.18 ± 0.35 |
| PED8 | WPH | 3.25 ± 0.23 | 46.95 ± 0.55 | 50.20 ± 2.55 |
| PED9 | WPH | 2.95 ± 0.05 | 54.08 ± 0.40 | 57.08 ± 0.83 |
| Median | 54.08 | 56.10 | ||
| Average Percentage | 3.99% | 96.01% | 100% | |
| Group 2 | ||||
| PED10 | SPH | tr | 39.03 ± 1.80 | 39.03 ± 1.80 |
| PED11 | SPH | nd | 16.23 ± 1.80 | 16.23 ± 1.80 |
| PED12 | SPH | tr | 31.63 ± 1.98 | 31.63 ± 1.98 |
| PED13 | SPH | 3.00 ± 0.20 | 15.35 ± 0.15 | 18.35 ± 1.10 |
| PED14 | SPH | 3.05 ± 0.30 | 23.40 ± 0.53 | 26.53 ± 1.53 |
| PED15 | SPH | nd | 31.00 ± 1.28 | 31.00 ± 1.28 |
| PED16 | SPH | nd | 31.43 ± 1.70 | 31.43 ± 1.70 |
| PED17 | SPH | 2.53 ± 0.10 | 27.08 ± 0.08 | 29.60 ± 2.58 |
| PED18 | SPH | tr | 31.65 ± 0.60 | 31.65 ± 0.60 |
| Median | 31.00 | 31.00 | ||
| Average Percentage | 3.39% | 96.61% | 100% | |
| Group 3 | ||||
| PED19 | CPH | 3.35 ± 0.80 | 31.18 ± 0.60 | 34.58 ± 1.78 |
| PED20 | CPH | tr | 30.70 ± 1.00 | 30.70 ± 1.00 |
| PED21 | CPH | nd | 33.73 ± 1.53 | 33.73 ± 1.53 |
| PED22 | CPH | nd | 35.38 ± 1.30 | 35.38 ± 1.30 |
| PED23 | CPH | nd | 29.65 ± 1.30 | 29.65 ± 1.30 |
| PED24 | CPH | tr | 46.98 ± 1.73 | 46.98 ± 1.73 |
| PED25 | CPH | 6.13 ± 0.28 | 22.55 ± 0.30 | 28.70 ± 0.73 |
| PED26 | CPH | nd | 39.23 ± 2.05 | 39.23 ± 2.05 |
| PED27 | CPH | nd | 42.18 ± 2.65 | 42.18 ± 2.65 |
| Median | 33.73 | 34.58 | ||
| Average Percentage | 2.98% | 97.02% | 100% |
(Value ± standard deviation; n = 3); nd, not detected; tr, trace amounts (between LOD and LOQ).
Figure 7Box plot with whiskers from minimum to maximum of Pep-Pyr concentration in different groups of peptides enriched drinks clustered to the type of peptides source. □ is the mean value. Different characters (a, b) on boxes indicate significant difference between groups (p < 0.05).
Protein content, total reducing sugar content and peptide lengths distribution in commercial PED samples.
| Group 1 (WPH) | Group 2 (SPH) | Group3 (CPH) | |
|---|---|---|---|
| Protein content (g/100 mL) | 4.0 ± 0.3 a | 3.6 ± 0.6 a | 3.9 ± 0.2 a |
| Total reducing sugar content (g/1000 mL) | 82.2 ± 5.0 a | 85.6 ± 3.6 a | 84.5 ± 6.3 a |
| Distribution of peptide lengths (%) | |||
| 1 (free amino acids) | 4.2 ± 0.3 a | 3.2 ± 1.1 b | 4.8 ± 1.4 a |
| 2–5 | 80.3 ± 1.0 a | 70.0 ± 2.0 b | 76.3 ± 1.5 c |
| 6–10 | 8.2 ± 1.2 a | 12.4 ± 1.3 b | 9.0 ± 0.8 a |
| 11–15 | 5.1 ± 0.9 a | 7.3 ± 5.8 a | 6.7 ± 0.2 a |
a–c Means ± standard deviation with different superscripts within same row indicate significant difference (p < 0.05).
Approximate essential amino acid profile of various protein sources [27].
| Essential Amino Acid | Whey Protein | Soy Protein | Collagen Protein |
|---|---|---|---|
| Ile | 5.5 | 4.9 | 1.7 |
| Leu | 14.2 | 8.2 | 3.4 |
| Lys | 10.2 | 6.3 | 4.1 |
| Met | 2.4 | 1.3 | 0.5 |
| Phe | 3.8 | 5.2 | 2.0 |
| Thr | 5.5 | 3.8 | 2.1 |
| Trp | 2.3 | 1.3 | na |
| Val | 5.9 | 5.0 | 3.0 |
| Total | 42.7 | 36.0 | 16.8 |
Approximate concentration of essential amino acids present within various forms of commercially available protein (g/100 g). na, indicates data not available.